Catalent Inc (NYSE:CTLT) – Stock analysts at William Blair reduced their FY2020 earnings per share (EPS) estimates for Catalent in a report issued on Monday, April 15th. William Blair analyst J. Kreger now expects that the company will earn $1.69 per share for the year, down from their previous forecast of $1.84.
CTLT has been the subject of a number of other reports. Zacks Investment Research lowered Catalent from a “buy” rating to a “hold” rating in a research note on Thursday, February 7th. First Analysis reaffirmed an “outperform” rating and set a $49.00 price target on shares of Catalent in a research note on Tuesday, March 5th. TheStreet raised Catalent from a “c” rating to a “b-” rating in a research note on Wednesday, February 6th. ValuEngine raised Catalent from a “hold” rating to a “buy” rating in a research note on Wednesday, February 20th. Finally, Jefferies Financial Group increased their price target on Catalent from $44.00 to $50.00 and gave the company a “hold” rating in a research note on Tuesday. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Catalent currently has an average rating of “Buy” and an average price target of $49.57.
Shares of NYSE CTLT opened at $43.97 on Thursday. The company has a debt-to-equity ratio of 1.36, a current ratio of 2.08 and a quick ratio of 1.63. The firm has a market cap of $6.47 billion, a price-to-earnings ratio of 27.65, a PEG ratio of 2.43 and a beta of 1.69. Catalent has a 1 year low of $29.23 and a 1 year high of $46.43.
Catalent (NYSE:CTLT) last issued its quarterly earnings results on Tuesday, February 5th. The company reported $0.45 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.37 by $0.08. The firm had revenue of $623.00 million during the quarter, compared to analyst estimates of $608.38 million. Catalent had a return on equity of 17.42% and a net margin of 5.48%. The firm’s quarterly revenue was up 2.8% on a year-over-year basis. During the same period last year, the company posted $0.45 EPS.
In other news, insider Aristippos Gennadios sold 3,392 shares of the firm’s stock in a transaction on Thursday, March 21st. The stock was sold at an average price of $42.18, for a total transaction of $143,074.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Lance Miyamoto sold 43,619 shares of the firm’s stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $42.49, for a total value of $1,853,371.31. The disclosure for this sale can be found here. Over the last three months, insiders have sold 54,326 shares of company stock valued at $2,303,676. Corporate insiders own 1.40% of the company’s stock.
Several institutional investors and hedge funds have recently added to or reduced their stakes in CTLT. Sageworth Trust Co acquired a new stake in shares of Catalent in the first quarter worth $32,000. Financial Gravity Wealth Inc. acquired a new stake in shares of Catalent in the first quarter worth $47,000. Quantamental Technologies LLC acquired a new stake in shares of Catalent in the fourth quarter worth $47,000. Bremer Trust National Association acquired a new stake in shares of Catalent in the fourth quarter worth $54,000. Finally, Enlightenment Research LLC acquired a new stake in shares of Catalent in the fourth quarter worth $56,000. 99.82% of the stock is owned by institutional investors and hedge funds.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Featured Article: What is a conference call?
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.